INTRODUCTION
============

Solid pancreatic lesions (SPLs), broadly classified as neoplastic and non-neoplastic lesions, are more frequently encountered in the course of routine radiology practice due to the increasingly widespread use of cross-sectional imaging for the evaluation of abdominal diseases ([@B1]). Among common SPLs, pancreatic ductal adenocarcinomas (PDACs), the fourth most common cause of cancer-related death in the United States ([@B2]), remains one of the most challenging tumors to treat ([@B3]). Until now, only 15--20% of patients with PDACs have potentially curative disease using margin-negative surgical resection at the time of diagnosis ([@B4][@B5][@B6]). Furthermore, although accurate and timely diagnosis of pancreatic malignancies is essential as it facilitates patient triage and guides the clinical management, precise characterization of small SPL is not always easy as they frequently show atypical imaging features ([@B7]).

Multiphasic multidetector computed tomography (MDCT) including arterial, pancreatic and hepatic venous phases has become a frontline technique for evaluation of a variety of pancreatic diseases, including PDAC ([@B8]), and is recommended as a primary diagnostic test by National Comprehensive Cancer Network Guidelines for staging of PDAC ([@B9]).

Although MR imaging is more vulnerable to the effect of motion and usually has lower spatial resolution than CT, its strength lies in its high-contrast resolution that is potentially useful for evaluating low-contrast SPLs ([@B10][@B11][@B12][@B13]). With recent advances in MRI technology, including higher field strength (3T), increasingly powerful multichannel coils, high resolution three-dimensional (3D) gradient-recalled echo (GRE) sequences and diffusion-weighted imaging (DWI), MRI may provide improved diagnostic accuracy for SPLs than before ([@B14][@B15][@B16]). However, to the best of our knowledge, only one previous study showed that CT was slightly better than MRI (CT = 88.4% vs. MRI = 75%, *p* = 0.388) without statistical significance in the diagnosis of small SPLs, but the major limitation was the small study population ([@B17]).

Therefore, the purpose of our study was to compare multiphasic MDCT and gadobutrol-enhanced MRI with regard to lesion conspicuity as well as the detection and characterization of small SPLs.

MATERIALS AND METHODS
=====================

Institutional Review Board approval was obtained, and informed patient consent was waived due to the retrospective nature of our study.

Patients
--------

The pathology and radiology databases of our medical institution were searched in order to identify patients with common SPLs diagnosed between January 2006 and August 2014, and we identified the patients who were pathologically confirmed to have a PDAC, neuroendocrine tumor (NET), solid pseudopapillary tumor (SPT) or pancreatic metastasis. We also searched the medical records in order to identify patients with mass-forming, autoimmune pancreatitis (AIP), who were diagnosed either by pathology or clinically according to the Asian diagnostic criteria ([@B18]), which are based on the combination of detected autoantibodies, elevated level of serum immunoglobulin G (IgG) or IgG4, and resolution or marked improvement of a pancreatic lesion after steroid therapy. Using these criteria, 679 patients with PDACs (n = 427), NETs (n = 124), SPTs (n = 83), AIPs (n = 20) or metastases (n = 25) were identified. Among the identified patients, 486 were excluded due to the following exclusion criteria: 1) SPLs with a diameter \> 3 cm in their longest dimension (n = 296), where the size of SPL was determined based on the pathologic report for the patients who underwent pancreatic surgery, or was measured on the preoperative CT or MR images for the patients who only underwent biopsy without surgical treatment ([@B14][@B15][@B19]), 2) patients who did not undergo both MDCT and MRI prior to surgery or treatment (n = 112), 3) CT and MRI protocols not including multiphasic dynamic imaging and DWI (n = 63), 4) patients who underwent CT examination on 4 channel-detector CT scanner (n = 3), 5) an interval between CT and MRI of longer than 60 days (n = 10), and 6) patients who had definite multiple liver or lung metastases, or diffuse peritoneal seeding as seen on CT or MRI, as these extra-pancreatic findings may suggest a diagnosis of malignancy (n = 2). Finally, 193 patients (M:F = 98:95; mean age, both 60 years) with underlying pancreatic diseases of PDACs (n = 127), NETs (n = 43), SPTs (n = 10), mass-forming AIPs (n = 7), or metastases (n = 6) comprised our study population. All 193 patients with SPL underwent histopathologic evaluation, which was based on surgically resected specimen for 185 patients (95.9%), and on needle biopsy specimen for 8 patients (4.1%, 5 PDACs and 3 mass-forming AIPs). The primary malignancies of the pancreatic metastases were as follows: renal cell carcinoma (n = 4), neuroendocrine carcinoma of the rectum (n = 1), and hepatocellular carcinoma (n = 1).

In order to evaluate the ability of CT and MRI in detecting SPLs, we searched the radiology databases and electronic medical records of our institution to identify patients with normal pancreas who underwent both MRI and CT using a pancreatobiliary protocol for non-pancreatic diseases. First, 4045 patients who underwent pancreatobiliary MRI from January 2006 to August 2014 in our institution were searched. Among these patients, 2860 patients were excluded due to the following reasons: patients without pancreatobiliary protocol CT (n = 219), abnormal finding at pancreas on CT or MRI (n = 2563), and overt liver or lung metastases, or diffuse peritoneal seeding on CT or MRI (n = 78). In addition, patients with abnormal finding at extrahepatic bile duct on CT or MRI (n = 1133) were excluded as SPL in pancreatic head portion can cause upstream bile ductal change (10, 12). As a result, 52 patients with normal pancreas (M:F = 27:25; mean age, 60 years) were included in this study. The indications for abdominal imaging in these patients were as follows: gallbladder diseases (n = 21); benign intrahepatic bile duct diseases (n = 17); workup for abdominal symptoms or laboratory parameter abnormalities (n = 10); and gastroduodenal disease (n = 4).

CT Technique
------------

Based on our pancreas protocol, contrast-enhanced CT scans including precontrast, arterial, pancreatic, and hepatic venous phases, were obtained using one of the following multi-detector CT scanners: 64-channel scanners (Brilliance 64, Philips Medical Systems, Cleveland, OH, USA; Somatom definition, Siemens Medical Solutions, Erlangen, Germany; Discovery CT750 HD, GE Healthcare, Milwaukee, WI, USA) for 176 patients, a 16-channel scanner (Sensation 16, Siemens Medical Solutions) for 65 patients, and an 8-channel scanner (LightSpeed Ultra, GE Healthcare) for 4 patients. The general scanning parameters were as follows: detector configurations of 64 × 0.6, 16 × 0.75, and 8 × 1.25 mm for the 64-, 16-, and 8-channel multi-detector, respectively; gantry rotation times of 0.5--0.75 second; tube currents of 150--200 mAs; tube voltage of 120 kVp; slice thicknesses of 3.0 mm; reconstruction intervals of 2--3 mm; and field of views of 300--390 mm.

For dynamic imaging, a total of 1.5 mL of nonionic contrast medium (iopromide \[370 mg of iodine per mL\], Ultravist 370; Schering, Berlin, Germany) per kilogram of body weight was administered at a rate of 2--5 mL/s using an automatic power injector (Multilevel CT, Medrad, Pittsburgh, PA, USA), followed by a 20 mL flush of sterile saline. For arterial phase imaging, the shortest scanning delay of 5 seconds was used after reaching a triggering threshold of 100 Hounsfield unit of aortic blood using an automatic bolus tracking technique. Pancreatic phase ([@B20]) scanning was then obtained for 22--24 seconds after the trigger threshold was reached, and the hepatic venous phase scan was obtained with a 70 second scanning delay following the contrast injection ([@B10][@B20]).

MRI Technique
-------------

MRI was performed using one of the following MR units, i.e., a 3T system (Verio, Siemens Healthcare; Ingenia, Philips Medical Systems) for 162 patients and 1.5T systems (Sonata, Siemens Healthcare; Signa Excite, GE Healthcare; Signa HDx, GE Healthcare) for 83 patients. Among these systems, the Verio and Signa Excite were the two most frequently used MR scanners and scanned 52.7% (129/245) and 22.9% (56/245) of the total study subjects, respectively. All MR sequence parameters used for these two scanners were summarized in [Table 1](#T1){ref-type="table"}.

Prior to contrast injection, T2-weighted (T2W) Half Fourier Acquisition Single Shot Turbo Spin Echo images, T1-weighted (T1W) in-phase and out-of phase 3D GRE images, respiratory-triggered DWI, and magnetic resonance cholangiopancreatography were obtained. Dynamic, fat-saturated, T1W 3D GRE imaging was performed before and after intravenous administration of 0.1 mmol/kg of gadobutrol (Gadovist, Gd-BT-DO3A, Schering, Berlin, Germany) per kilogram of the patient\'s body weight at an injection rate of 1.5 mL/sec. Intravenous injection of contrast agent was performed using a power injector (Stellent Dual, Siemens Medical Solutions) and was followed by a flush of 20 mL of normal saline. The scanning times of each phase of the dynamic study were determined using real-time MR fluoroscopy as follows: arterial, pancreatic, hepatic venous, and delayed phase images were obtained serially at 5 seconds, 25 seconds, and 55 seconds after contrast arrival to the abdominal aorta detected using an MR fluoroscopy technique ([@B21][@B22]). DWI was performed using multisection single-shot, spin-echo, echo-planar imaging with a spectral presaturation attenuated inversion-recovery, and fat-suppressed pulse sequence. For 1.5T units, b values of 0, 500, and 1000 s/mm^2^ were used, and b values of 0, 25, 50, 75, 100, 150, 200, 500, 800, and 1000 s/mm^2^ were used for 3T units.

Image Analysis
--------------

All CT and MR images were reviewed on a PACS workstation monitor (m-view, Marotech) by two attending abdominal radiologists, who had 17 and 7 years, respectively, of clinical experience in the interpretation of body CT and MRI. Both blinded reviewers independently reviewed the CT and MR image sets with a two-week interval between the two interpretation sessions in order to minimize any learning bias. CT and MR images were randomly presented during each interpretation session to ensure that there was no predictable order between the two data sets. Both reviewers knew that each of the study patients may or may not have a SPL, although the reviewers were blinded to the other patients\' clinical information and histopathologic results.

The detection of the SPL was determined twice in two different ways: 1) detection of SPL \"per se\", and 2) detection of SPL \"in consideration of secondary features\".

First, the reviewers determined the presence or absence of SPL per se. If a discernible focal mass-like lesion in the pancreas parenchyma that shows different attenuation or signal intensity compared to normal pancreatic parenchyma on at least one of the images of various phases and sequences, reviewers determined that SPL per se is present. On the basis of these results, the sensitivity, specificity, and accuracy for \"detection of SPL per se\" were calculated.

Thereafter, the reviewers determined the presence or absence of SPL in consideration of secondary features such as pancreatic ductal changes, parenchymal atrophy, or peripancreatic soft tissue infiltration. For example, when CT images show no discernible focal pancreatic lesions but only abrupt narrowing of the main pancreatic duct at pancreatic neck portion and upstream ductal dilatation, the reviewers scored that SPL per se was not detected, but SPL was detected in consideration of secondary features ([Fig. 1](#F1){ref-type="fig"}). On the basis of these results, the sensitivity, specificity, and accuracy for \"detection of SPL in consideration of secondary features\" were calculated.

For the cases where SPL per se was detected, the conspicuity of SPL was further specified using a three-point scale: 1, poor, i.e., faint perceptibility of the lesion, difficult to detect; 2, good, i.e., easily recognizable lesion, unequivocal perceptibility; and 3, excellent, i.e., excellent lesion perceptibility ([Fig. 2](#F2){ref-type="fig"}). The lesion conspicuity was determined on most perceptible phase or sequence among all the images.

In addition, the diagnostic performance of MDCT and MRI for differentiating PDACs and non-PDACs was evaluated, considering that PDACs account for 90% of malignancies of the pancreas, requires radical pancreatectomy including regional lymphadenectomy, as well as meticulous dissection along the perivascular nerve tissue and retroperitoneum, and carry a more grave prognosis compared to those of other SPLs ([@B2][@B5]). The reviewers recorded their diagnostic confidence with reference to the probability of PDAC using a 5-point scale: 5, definitely PDAC; 4, probably PDAC; 3, possibly PDAC; 2, probably other; 1, definitely other ([@B23]). The diagnosis of PDAC was based on well-known imaging features presented in the published literature including low attenuation on CT, low signal intensity on T1W images, poor enhancement on dynamic studies, ill-defined margin, upstream pancreatic ductal dilatation, and parenchymal atrophy ([@B1][@B3][@B10][@B24][@B25]).

Finally, both reviewers were asked to suggest a most likely diagnosis based on the following six possible choices: PDAC; NET; SPT; mass-forming AIP; metastasis; and normal pancreas, based on the well-documented, characteristic imaging features summarized in [Table 2](#T2){ref-type="table"} ([@B14][@B15][@B16][@B19][@B26][@B27][@B28][@B29][@B30][@B31][@B32]).

Histopathologic Analysis
------------------------

Pathology evaluation of surgically resected or biopsy specimens served as a standard of reference for the accurate diagnosis of SPLs. All histopathologic specimens were reviewed by an attending pathologist who had more than 10 years of clinical experience in pancreatobiliary diseases.

Statistical Analysis
--------------------

The sensitivity, specificity and accuracy of CT and MRI for detecting SPLs were calculated and compared using the McNemar test. Differences in the lesion conspicuity of the two imaging techniques for each reviewer were evaluated using the Wilcoxon signed rank test. In addition, receiver operating characteristic (ROC) analysis and pairwise comparison of ROC curves were performed to evaluate the overall performance of the two imaging techniques for diagnosing PDAC vs. other SPLs ([@B23]). The accuracy CT and MRI for specific diagnosis was calculated and compared using the McNemar test. Interobserver agreement was analyzed for each review item using kappa statistics. Weighted kappa with linear weights was applied for ordinal data. Kappa values of less than 0.20 indicated slight agreement, 0.21--0.40 fair agreement, 0.41--0.60 moderate agreement, 0.61--0.80 substantial agreement, and more than 0.80 almost perfect agreement. For all analyses, *p* values ≤ 0.05 were considered as statistically significant difference. SPSS 19.0 software (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses except ROC analysis and kappa statistics, which were performed using MedCalc software (MedCalc, Mariakerke, Belgium).

RESULTS
=======

Sensitivity, Specificity, and Accuracy for Detection of SPL
-----------------------------------------------------------

The sensitivity, specificity, and accuracy for \"detection of SPL per se\" and \"detection of SPL in consideration of secondary features\" were presented in [Table 3](#T3){ref-type="table"}.

The sensitivity of MRI for \"detection of SPL per se\" was significantly higher than that of CT in both reviewers: 92.7% (179/193) and 97.9% (189/193), respectively, for reviewer 1 (*p* = 0.031) and 90.7% (175/193) and 99.5% (192/193), respectively, for reviewer 2 (*p* \< 0.001) ([Fig. 3](#F3){ref-type="fig"}). The specificity of both CT and MRI for \"detection of SPL per se\" was equally 100.0% (52/52) for both reviewers.

However, the sensitivity of CT and MRI for \"detection of SPL in consideration of secondary features\" was not significantly different for both reviewers: 97.9% (189/193) and 97.9% (189/193), respectively, for reviewer 1 and 97.4% (188/193) and 99.5% (192/193), respectively, for reviewer 2 (*p* = 0.219). In addition, the specificity of CT and MRI did not differ significantly for \"detection of SPL in consideration of secondary features\" for both reviewers: 96.2% (50/52) and 98.1% (51/52), respectively, for reviewer 1 (*p* = 1.000), and both 100.0% (52/52) for reviewer 2.

Lesion Conspicuity
------------------

For both reviewers, SPLs were significantly more conspicuous on MRI than on CT (*p* \< 0.001). The lesion conspicuity for each specific diagnosis reported by both reviewers was presented in [Table 4](#T4){ref-type="table"}.

ROC Analysis for Differentiating PDAC vs. Non-PDAC
--------------------------------------------------

CT and MRI did not show significant difference in determining the probability of PDAC for both reviewers: the area under the curves of CT and MRI were 0.934 (95% confidence interval \[CI\]: 0.895--0.961) and 0.955 (95% CI: 0.921--0.977) for reviewer 1 (*p* = 0.173), respectively, and 0.967 (95% CI: 0.937--0.986) and 0.973 (95% CI: 0.944--0.989), respectively, for reviewer 2 (*p* = 0.693).

Accuracy of CT and MRI for Specific Diagnosis
---------------------------------------------

The accuracy of CT and MRI for specific diagnosis was not significantly different for both readers: 85.7% (210/245) and 86.9% (213/245), respectively, for reviewer 1 (*p* = 0.736) and 91.8% (225/245) and 93.5% (229/245), respectively, for reviewer 2 (*p* = 0.454). The numbers of correct diagnoses for each specific diagnosis for both reviewers are summarized in [Table 5](#T5){ref-type="table"}.

Inter-Observer Agreement
------------------------

The results of inter-observer agreements showed almost perfect agreement between the two reviewers except the probability of PDAC evaluated on MRI (k = 0.792). The kappa values on CT and MRI were 0.939 and 0.941 for detection of SPL per se; 0.965 and 0.929 for detection of SPL in consideration of secondary features; 0.894 and 0.815 for lesion conspicuity; 0.807 and 0.792 for the probability of PDAC; and 0.865 and 0.832 for specific diagnosis, respectively ([Table 6](#T6){ref-type="table"}).

DISCUSSION
==========

The results of our study demonstrated that, the sensitivity for \"detection of SPL per se\" and lesion conspicuity are significantly higher on MRI than on CT imaging. This superiority of MRI in visualization of parenchymal lesion might be explained by the additional benefit derived from the fat-suppressed T1W sequence and DWI, as well as high-contrast resolution of MRI ([@B33][@B34][@B35]). Previous studies demonstrated that fat-suppressed T1W images are able to provide high contrast between pancreatic solid tumors and background pancreatic parenchyma having high signal intensity due to the presence of proteins and manganese, as compared with T2W images or postcontrast T1W images ([@B36][@B37]). In addition, several reports suggested the usefulness of DWI in detecting PDAC ([@B35][@B38]).

In our study, PDAC accounted for 65.8% (127/193) of all SPLs, and the difference in sensitivity of CT and MRI for detection of SPL per se was largely due to the different sensitivity for \"PDAC per se\" while other SPLs did not show significant difference in sensitivities between two modalities ([Table 3](#T3){ref-type="table"}). Several previous studies showed that a small subset of PDAC is indistinguishable from normal pancreatic parenchyma on CT, which is called \"visually isoattenuating PDAC\" ([@B12][@B39][@B40]). The result of our study corroborates previous reports as the difference in sensitivity of CT and MRI for detection of PDAC per se (7.1% for reviewer 1 and 10.2% for reviewer 2) is similar to the reported prevalence (5.4--14.0%) of \"visually isoattenuating PDAC\" ([@B12][@B39][@B40]). Nevertheless, the sensitivity of CT and MRI for detection of PDAC in consideration of secondary features did not differ significantly in our study. This discrepancy between the sensitivity for detection of PDAC per se and detection of PDAC in consideration of secondary features suggest the important role of secondary findings in detection of PDAC, as emphasized in previous reports ([@B12][@B39]).

In addition, the diagnostic performance of CT and MRI for determining the probability of PDAC and for making specific diagnosis did not show significant difference in our study (*p* \> 0.05). Our results supported the results of the previous study by Rao et al. ([@B17]) in that both studies showed no significant difference in accuracy of CT and MRI for diagnosing small SPLs (CT = 88.4% vs. MRI = 75%, *p* = 0.388).

In our study, MRI showed better lesion conspicuity than MDCT, but did not show significantly different diagnostic accuracy for specific diagnosis compared with MDCT. This discrepancy between the lesion conspicuity and diagnostic accuracy may be explained by the following. First, common SPLs such as PDAC, NET, or SPT show quite different enhancement patterns from each other, which can be well evaluated with contrast enhanced multiphasic ultrasonography, CT or MRI, despite overlapped morphologic features on unenhanced imaging ([@B7][@B41][@B42]). Second, it is possible that superior soft-tissue contrast resolution of MRI, which primarily contributed to the higher lesion conspicuity, may be countered by lower spatial resolution compared with the same factors on CT imaging ([@B43][@B44]).

Our study results suggest that MRI currently cannot replace CT for evaluation of small SPLs, because of its higher cost and longer acquisition time compared to those of CT. However, considering the better sensitivity for \"detection of SPL per se\" and better lesion conspicuity on MRI than on CT, the use of MRI can be justified if SPLs are strongly suspicious but SPLs are not visually identified on CT.

Our study has several limitations. First, due to its retrospective nature, there may have been a selection bias. Second, as our study had a relatively small number of patients with SPTs, mass-forming AIPs, and pancreatic metastases, it will be necessary to conduct further studies with a larger study population in order to validate our findings. Third, the scanners for pancreatic CT and MRI were also variable. However, we believe that this was not a major limitation to our study as only qualitative analysis of the images was performed without any quantitative analysis. Fourth, although all study patients underwent MRI with DWI, we did not evaluate the diagnostic performance of MRI with DWI compared to that of MRI without DWI. In addition, quantitative analysis of apparent diffusion coefficient (ADC) was not performed in this study. Considering several reports indicating that ADC may help to differentiate PDAC, chronic pancreatitis, and normal pancreas ([@B13][@B35][@B44][@B45][@B46][@B47]), this quantitative analysis may possibly provide additional benefits in the detection and characterization of SPLs. Finally, when the reviewers analyze the detection of SPL per se, they were asked to determine the presence or absence of the lesion without considering secondary features that may assist in diagnosis. We acknowledge that there may be a certain degree of systematic bias because it often may not be possible to dispel these secondary features while remaining completely unbiased as to the presence or absence of SPL per se.

In conclusion, gadobutrol-enhanced MRI showed better lesion conspicuity than MDCT, but did not show significantly different diagnostic performance compared with MDCT for detecting and characterizing small SPLs.

![81-year-old woman with pancreatic ductal adenocarcinoma.\
**A.** Axial, post-contrast CT image obtained during hepatic venous phase shows dilatation of main pancreatic duct with abrupt narrowing (arrow) at neck portion of pancreas. However no definite focal pancreatic mass lesion obstructing main pancreatic duct is visualized on CT. Both reviewers answered that SPL per se was not detected on CT images. However, main pancreatic ductal change led both reviewers to detection of SPL in consideration of secondary features and to correct diagnosis. **B.** Axial, fat-suppressed, T2-weighted image demonstrates dilatation of main pancreatic duct (arrowheads) and abrupt narrowing (arrow) without definite parenchymal lesion at neck portion of pancreas. **C.** Axial, fat--suppressed, T1-weighted image shows approximately 1 cm sized ill-defined, subtle hypointensity lesion (arrow) in neck portion of pancreas. **D.** Axial, post-contrast, T1-weighted image obtained during pancreatic phase, shows no definite mass lesion in pancreas. In addition, diffusion-weighted image did not show definite focal lesion in pancreas (not shown). Both reviewers reported SPL per se as detectable on MR image with poor lesion conspicuity graded as 1, and their specific diagnosis was pancreatic ductal adenocarcinoma. SPL = solid pancreatic lesion](kjr-17-509-g001){#F1}

![Representative figures for each conspicuity category from six different patients with pancreatic ductal adenocarcinoma.\
**A, B,** and C demonstrate axial CT images obtained during pancreatic phase and **D, E,** and **F** show axial fat-suppressed non-enhanced T1-weighted MR images. Conspicuity of lesion (arrows) is 1, poor, i.e., faint perceptibility of lesion, on **A** and **D**; 2, good, i.e., easily recognizable, on **B** and **E**; and 3, excellent, i.e., excellent lesion perceptibility, on **C** and **F**.](kjr-17-509-g002){#F2}

![40-year-old woman with pancreatic neuroendocrine tumor, grade 1.\
**A.** Axial, post-contrast CT image obtained during pancreatic phase shows subtle, slightly high attenuated lesion (arrow) in tail portion of pancreas. On CT, both reviewers were not able to detect \"SPL in consideration of secondary features\" as well as \"SPL per se\". **B.** Axial, fat-suppressed, T2-weighted image demonstrates approximately 1.5 cm sized hyperintense lesion (arrow) at pancreatic tail. **C.** On axial, fat--suppressed, non-enhanced T1-weighted image, lesion (arrow) shows marked hypointensity compared to that of pancreas parenchyma. **D, E.** Axial, diffusion-weighted image with b value of 800 sec/mm^2^ **(D)** and apparent diffusion constant map **(E)** also demonstrate hyperintense lesion (arrows) with diffusion restriction. On MRI, both reviewers were able to detect SPL per se and made correct specific diagnosis. Lesion conspicuity was excellent for reviewer 1, and good for reviewer 2. SPL = solid pancreatic lesion](kjr-17-509-g003){#F3}

###### MR Parameters

![](kjr-17-509-i001)

                   T1WI (OP/IP)        T2WI                DWI         Thick Slab MRCP   3D MRCP     Dynamic Image                                                                  
  ---------------- ------------------- ------------------- ----------- ----------------- ----------- --------------- -------------- ----------- ----------- ----------- ----------- -----------
  TR/TE (msec)     4.0/1.3 & 4.0/2.3   170/2.0 & 170/4.2   800/93      752/92            4500/52     3275/81.9       2500/909       4000/999    2320/815    4000/875    3.4/1.2     5.0/2.2
  ETL              1                   1                   256         1                 1           1               256            1           69          1           1           1
  FA               9°                  60°                 130°        90°               180°        90°             130° or 180°   90°         130°        90°         11°         12°
  Thickness (mm)   3                   7                   7           7                 7           7               50 or 60       60          0.9         2           3           4.8
  FOV (mm)         300-380             260-380             300-380     300-380           380         380             240            260         380         250-320     300-380     300-380
  Matrix           320 × 285           320 × 224           384 × 307   320 × 256         256 × 205   144 × 144       320 × 256      384 × 256   384 × 366   320 × 320   384 × 278   320 × 224

Scanner 1 = Verio, Siemens Medical Solution; Scanner 2 = Signa Excite, GE Medical System. DWI = diffusion-weighted images, ETL = echo train length, FA = flip angle, FOV = field of view, IP = in-phase, MRCP = magnetic resonance cholangiopancreatography, OP = opposed-phase, TE = echo time, TR = repetition time, T1WI = T1-weighted images, T2WI = T2-weighted images, 3D = three-dimensional

###### Characteristic Imaging Features of Each of Solid Pancreatic Lesions Used for Making Specific Diagnosis

![](kjr-17-509-i002)

  Diagnosis                                                                                                                                   Characteristic Imaging Features
  ------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------
  PDAC                                                                                                                                        Low signal intensity on fat suppressed T1W images
  Poor enhancement on dynamic studies                                                                                                         
  Ill-defined margin                                                                                                                          
  Upstream pancreatic ductal dilatation and parenchymal atrophy with/without bile duct obstruction                                            
  NET                                                                                                                                         Hyperenhancement than pancreas parenchyma on the arterial and/or pancreatic phase
  Discrete margin and lack of adjacent vascular invasion                                                                                      
  Absence or mild degree of pancreatic ductal dilatation                                                                                      
  SPT                                                                                                                                         Strong prevalence among middle-aged women
  Well-defined margin                                                                                                                         
  Intratumoral high signal intensity on fat suppressed T1W images, suggestive of hemorrhage                                                   
  Early, heterogeneous, slowly progressive enhancement pattern                                                                                
  Mass-forming AIP                                                                                                                            Hypoenhancing mass like lesion during dynamic phases
  Capsule-like rim enhancement                                                                                                                
  Delayed enhancement                                                                                                                         
  Absence of bile-duct or pancreatic duct stricture                                                                                           
  Irregular or geographic shape rather than round, oval or lobulated shape                                                                    
  Metastasis                                                                                                                                  Multiple solid pancreatic lesions
  Stronger enhancing masses than pancreas parenchyma if primary malignancy is RCC (evidence of previous nephrectomy or partial nephrectomy)   
  Hypoenhancing masses if primary malignancy is not RCC                                                                                       
  Discrete margin                                                                                                                             

AIP = autoimmune pancreatitis, NET = neuroendocrine tumor, PDAC = pancreatic ductal adenocarcinoma, RCC = renal cell carcinoma, SPT = solid pseudopapillary tumor, T1W = T1-weighted

###### Sensitivity, Specificity, and Accuracy for Detection of SPLs on MDCT and MRI

![](kjr-17-509-i003)

                                                            Reviewer 1        *P*^\*^           Reviewer 2   *P*^\*^                             
  --------------------------------------------------------- ----------------- ----------------- ------------ ----------------- ----------------- ----------
  Detection of SPL per se                                                                                                                        
   Sensitivity                                              92.7% (179/193)   97.9% (189/193)   0.031        90.7% (175/193)   99.5% (192/193)   \< 0.001
    PDAC                                                    92.1% (117/127)   99.2% (126/127)   0.012        89.0% (113/127)   99.2% (126/127)   \< 0.001
    NET                                                     95.3% (41/43)     93.0% (40/43)     1.000        95.3% (41/43)     100.0% (43/43)    0.500
    SPT                                                     100.0% (10/10)    100.0% (10/10)    \-           100.0% (10/10)    100.0% (10/10)    \-
    Mass-forming AIP                                        71.4% (5/7)       100.0% (7/7)      0.500        71.4% (5/7)       100.0% (7/7)      0.500
    Metastasis                                              100.0% (6/6)      100.0% (6/6)      \-           100.0% (6/6)      100.0% (6/6)      \-
   Specificity                                              100.0% (52/52)    100.0% (52/52)    \-           100.0% (52/52)    100.0% (52/52)    \-
   Accuracy                                                 94.3% (231/245)   98.4% (241/245)   0.031        92.7% (227/245)   99.6% (244/245)   \< 0.001
  Detection of SPL in consideration of secondary features                                                                                        
   Sensitivity                                              97.9% (189/193)   97.9% (189/193)   1.000        97.4% (188/193)   99.5% (192/193)   0.219
    PDAC                                                    99.2% (126/127)   99.2% (126/127)   1.000        98.4% (125/127)   99.2% (126/127)   1.000
    NET                                                     95.3% (41/43)     93.0% (40/43)     0.500        95.3% (41/43)     100.0% (43/43)    0.500
    SPT                                                     100.0% (10/10)    100.0% (10/10)    \-           100.0% (10/10)    100.0% (10/10)    \-
    Mass-forming AIP                                        85.7% (6/7)       100.0% (7/7)      1.000        85.7% (6/7)       100.0% (7/7)      1.000
    Metastasis                                              100.0% (6/6)      100.0% (6/6)      \-           100.0% (6/6)      100.0% (6/6)      \-
   Specificity                                              96.2% (50/52)     98.1% (51/52)     1.000        100.0% (52/52)    100.0% (52/52)    \-
   Accuracy                                                 97.6% (239/245)   98.0% (240/245)   1.000        98.0% (240/245)   99.6% (244/245)   0.219

^\*^*p*-value was obtained between CT and MRI using McNemar test. AIP = autoimmune pancreatitis, MDCT = multidetector computed tomography, NET = neuroendocrine tumor, PDAC = pancreatic ductal adenocarcinoma, SPL = solid pancreatic lesion, SPT = solid pseudopapillary tumor

###### Conspicuity of SPLs on MDCT and MRI

![](kjr-17-509-i004)

                     No. of Patients   Reviewer     CT           MR           *P*^\*^                                                                         
  ------------------ ----------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------- ------------ ------------- ----------
  All SPL            193               1            14 (7.3%)    55 (28.5%)   66 (34.2%)   58 (30.0%)   4 (2.1%)     16 (8.3%)     41 (21.2%)   132 (68.4%)   \< 0.001
  2                  18 (9.3%)         48 (24.9%)   63 (32.6%)   64 (33.2%)   1 (0.5%)     16 (8.3%)    67 (34.7%)   109 (56.5%)   \< 0.001                   
  PDAC               127               1            10 (7.9%)    46 (36.2%)   50 (39.4%)   21 (16.5%)   1 (0.8%)     16 (12.6%)    32 (25.2%)   78 (61.4%)    \< 0.001
  2                  14 (11.0%)        43 (33.9%)   48 (37.8%)   22 (17.3%)   1 (0.8%)     15 (11.8%)   53 (41.7%)   58 (45.7%)    \< 0.001                   
  NET                43                1            2 (4.7%)     7 (16.3%)    9 (20.9%)    25 (58.1%)   3 (7.0%)     0 (0.0%)      4 (9.3%)     36 (83.7%)    0.055
  2                  2 (4.7%)          3 (7.0%)     9 (20.9%)    29 (67.4%)   0 (0.0%)     0 (0.0%)     9 (20.9%)    34 (79.1%)    0.344                      
  SPT                10                1            0 (0.0%)     0 (0.0%)     2 (20.0%)    8 (80.0%)    0 (0.0%)     0 (0.0%)      0 (0.0%)     10 (100.0%)   0.500
  2                  0 (0.0%)          0 (0.0%)     1 (10.0%)    9 (90.0%)    0 (0.0%)     0 (0.0%)     0 (0.0%)     10 (100.0%)   1.000                      
  Mass-forming AIP   7                 1            2 (28.6%)    2 (28.6%)    3 (42.8%)    0 (0.0%)     0 (0.0%)     0 (0.0%)      3 (42.9%)    4 (57.1%)     0.063
  2                  2 (28.6%)         2 (28.6%)    3 (42.8%)    0 (0.0%)     0 (0.0%)     1 (14.3%)    4 (57.1%)    2 (28.6%)     0.125                      
  Metastasis         6                 1            0 (0.0%)     0 (0.0%)     2 (33.3%)    4 (66.7%)    0 (0.0%)     0 (0.0%)      2 (33.3%)    4 (66.7%)     1.000
  2                  0 (0.0%)          0 (0.0%)     2 (33.3%)    4 (66.7%)    0 (0.0%)     0 (0.0%)     1 (16.7%)    5 (83.3%)     1.000                      

^\*^*p*-value was obtained between CT and MRI for each reviewer by using Wilcoxon signed rank test. AIP = autoimmune pancreatitis, MDCT = multidetector computed tomography, NET = neuroendocrine tumor, PDAC = pancreatic ductal adenocarcinoma, SPL = solid pancreatic lesion, SPT = solid pseudopapillary tumor

###### Accuracy of CT and MRI for Making Specific Diagnosis

![](kjr-17-509-i005)

  Diagnosis          No. of Patients   Reviewer 1    Reviewer 2                                        
  ------------------ ----------------- ------------- ------------- ------- ------------- ------------- -------
  PDAC               127               117 (92.1%)   117 (92.1%)   1.000   122 (96.1%)   120 (94.5%)   0.727
  NET                43                31 (72.1%)    29 (67.4%)    0.754   34 (79.1%)    39 (90.7%)    0.063
  SPT                10                7 (70.0%)     9 (90.0%)     0.500   9 (90.0%)     9 (90.0%)     1.000
  Mass-forming AIP   7                 0 (0.0%)      3 (42.9%)     0.250   3 (42.9%)     4 (57.1%)     1.000
  Metastasis         6                 5 (83.3%)     4 (66.7%)     1.000   5 (83.3%)     5 (83.3%)     \-
  Normal             52                50 (96.2%)    51 (98.1%)    1.000   52 (100.0%)   52 (100.0%)   \-
  Overall            245               210 (85.7%)   213 (86.9%)   0.736   225 (91.8%)   229 (93.5%)   0.454

^\*^*p*-value was obtained between CT and MRI using McNemar test. AIP = autoimmune pancreatitis, NET = neuroendocrine tumor, PDAC = pancreatic ductal adenocarcinoma, SPT = solid pseudopapillary tumor

###### Inter-Observer Agreement

![](kjr-17-509-i006)

  Review Item                                               Kappa Value (95% Confidence Interval)   
  --------------------------------------------------------- --------------------------------------- -------------------------
  Detection of SPL per se                                   0.939 (0.891-0.987)                     0.941 (0.890-0.992)
  Detection of SPL in consideration of secondary features   0.965 (0.926-1.000)                     0.929 (0.872-0.985)
  Conspicuity of SPL                                        0.894 (0.858-0.931)^\*^                 0.815 (0.761-0.870)^\*^
  Probability of PDAC                                       0.807 (0.758-0.856)^\*^                 0.792 (0.744-0.839)^\*^
  Specific diagnosis                                        0.865 (0.811-0.919)                     0.832 (0.774-0.890)

^\*^Weighted Kappa value with linear weights was calculated. PDAC = pancreatic ductal adenocarcinoma, SPL = solid pancreatic lesion
